Trial Profile
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary) ; GPC3-CAR-T (Primary) ; Satricabtagene autoleucel (Primary) ; Sorafenib (Primary) ; Zevorcabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Adenocarcinoma; B-cell leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; Carcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Liver cancer; Mantle-cell lymphoma; Multiple myeloma; Oesophageal cancer; Pancreatic cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions
- 15 Jan 2024 According to a CARsgen media release, CT011 received IND clearance from the NMPA in 2019 for the treatment of patients with GPC3-positive solid tumor.
- 18 Aug 2022 According to a CARsgen media release, a case report titled "Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, A case report", has been published in Frontiers in Immunology.
- 18 Aug 2022 Results published in the CARsgen Media Release.